NCT05696548View on ClinicalTrials.gov

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

Lenvatinib

Lenvatinib will be administered at a dose of 24mg as oral dose, one a day

DRUG

Nivolumab

Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks

Trial Locations (10)

464-8681

Aichi Cancer Center, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa

060-8648

Hokkaido University Hospital, Hokkaido

673-8558

Hyogo Cancer Center, Akashi

650-0017

Kobe University Hospital, Kobe

236-0004

Yokohama City University Hospital, Yokohama

980-8574

Tohoku University Hospital, Sendai

545-8586

Osaka Metropolitan University Hospital, Osaka

104-0045

National Cancer Center Hospital, Tokyo

113-8603

Nippon Medical School Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

National Cancer Center Hospital East

OTHER

NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | Biotech Hunter | Biotech Hunter